Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Atezolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention. Browse Atezolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
512
Shown on this page
12
Current sort
Recently updated
Therapy scope
Atezolizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Atezolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 433–444 of 512 matching trials for Atezolizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Completed Phase 1 Interventional Results available

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

NCT03178851
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

NCT04422210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Venetoclax, Atezolizumab, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

NCT03179943
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Guadecitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

NCT02792192
View directory record Official record
Conditions
Bladder Cancer
Interventions
Atezolizumab, Bacille Calmette-Guérin
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Completed Phase 1 Interventional

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

NCT03056599
View directory record Official record
Conditions
Soft Tissue Sarcoma Adult
Interventions
Multiple drug microinjection, CIVO device
Drug · Device
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Lake Success, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02366143
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
61
States / cities
Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Withdrawn Phase 2 Interventional

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

NCT04020094
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
MVA-BN-Brachyury
Combination Product
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

NCT03115801
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Completed Phase 1 Interventional

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822
View directory record Official record
Conditions
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
Ciforadenant, Ciforadenant + atezolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

NCT03394885
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Atezolizumab, Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 31, 2026, 7:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

NCT03566485
View directory record Official record
Conditions
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative
Interventions
Atezolizumab, Cobimetinib, Idasanutlin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 31, 2026, 7:04 PM EDT

About this Atezolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Atezolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Atezolizumab.